Lipid-Based Drug Delivery Systems in Regenerative Medicine

Filipczak, Nina; Yalamarty, Satya Siva Kishan; Li, Xiang; Khan, Mudasser Muneer; Parveen, Farzana; Torchilin, Vladimir P.

doi:10.3390/ma14185371

Cited by 19 publications

(9 citation statements)

References 167 publications

(167 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, polyelectrolyte microparticles, which can be controlled by various external actions (140) and have advanced release capabilities (141), have been reported to be effective enhancer of antigen cross-presentation in porcine dendritic cells (142). Further, lipid-based formulations (143,144), anisotropic (145), multicompartment (146), anisotropic multicompartment (147) carriers, soft and hard nanocarriers (148) are some of the candidates for incorporating advanced functionalities for immunology. • Among different types of carriers, theragnostic drug delivery vehicles (149) are seen to be a particularly valuable type of carriers due to their dual function: diagnostic or sensoric (150) as well as therapeutic functions.…”

Section: Conclusion and Final Remarksmentioning

confidence: 99%

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy

et al. 2022

View full text Add to dashboard Cite

Immunogenic cell death (ICD) is a rapidly growing research area representing one of the emerging therapeutic strategies of cancer immunotherapy. ICD is an umbrella term covering several cell death modalities including apoptosis, necroptosis, ferroptosis and pyroptosis, and is the product of a balanced combination of adjuvanticity (damage-associated molecular patterns and chemokines/cytokines) and antigenicity (tumor associated antigens). Only a limited number of anti-cancer therapies are available to induce ICD in experimental cancer therapies and even much less is available for clinical use. To overcome this limitation, nanomaterials can be used to increase the immunogenicity of cancer cells killed by anti-cancer therapy, which in themselves are not necessarily immunogenic. In this review, we outline the current state of knowledge of ICD modalities and discuss achievements in using nanomaterials to increase the immunogenicity of dying cancer cells. The emerging trends in modulating the immunogenicity of dying cancer cells in experimental and translational cancer therapies and the challenges facing them are described. In conclusion, nanomaterials are expected to drive further progress in their use to increase efficacy of anti-cancer therapy based on ICD induction and in the future, it is necessary to validate these strategies in clinical settings, which will be a challenging research area.

show abstract

Section: Conclusion and Final Remarksmentioning

confidence: 99%

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…By employing liposomes as non-viral vectors, the unaltered gene can be delivered to the target cell. The transport of proteins and peptides into the cytoplasm of dendritic cells by endocytosis has extensively used liposome vesicles [ 5 ]. Since they do not contain any proteins, liposomes have an advantage over non-viral carriers and vectors in preventing immunological reactions.…”

Section: Lipid Nanoparticlesmentioning

confidence: 99%

“…Nanoformulations are indisputably valuable tools for drug delivery [ 4 ]. Since lipid nanoparticles are frequently viewed as non-toxic, biocompatible, and simple to create formulations, they have gained popularity in this context [ 5 ]. Lipid nanocarriers are increasingly used in the pharmaceutical industry to transport and deliver a variety of therapeutic agents, from biotechnological products to small drug molecules [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Lipid Nanoparticles and Liposomes for Bone Diseases Treatment

Burdușel

Andronescu

2022

Biomedicines

View full text Add to dashboard Cite

Because of their outstanding biocompatibility, sufficient capacity to control drug release, and passive targeting capability, lipid nanoparticles are one of the world’s most widely utilized drug delivery systems. However, numerous disadvantages limit the use of lipid nanoparticles in clinical settings, especially in bone regeneration, such as challenges in transporting, storing, and maintaining drug concentration in the local area. Scaffolds are frequently employed as implants to provide mechanical support to the damaged area or as diagnostic and imaging tools. On the other hand, unmodified scaffolds have limited powers in fostering tissue regeneration and curing illnesses. Liposomes offer a solid foundation for the long-term development of various commercial solutions for the effective drug delivery-assisted treatment of medical conditions. As drug delivery vehicles in medicine, adjuvants in vaccination, signal enhancers/carriers in medical diagnostics and analytical biochemistry, solubilizers for various ingredients as well as support matrices for various ingredients, and penetration enhancers in cosmetics are just a few of the industrial applications for liposomes. This review introduces and discusses the use of lipid nanoparticles and liposomes and the application of lipid nanoparticles and liposome systems based on different active substances in bone diseases.

show abstract

“…Lipid-based drug delivery systems (LBDDS) are formulations containing a dissolved or suspended drug substance in lipidic excipients [66]. LBDDS are a progressive strategy to formulate pharmaceuticals for topical delivery [67].…”

Section: Lipid-based Drug Delivery Systemsmentioning

confidence: 99%

Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders

Stefanov

Andonova

2021

Pharmaceuticals

View full text Add to dashboard Cite

The multifunctional role of the human skin is well known. It acts as a sensory and immune organ that protects the human body from harmful environmental impacts such as chemical, mechanical, and physical threats, reduces UV radiation effects, prevents moisture loss, and helps thermoregulation. In this regard, skin disorders related to skin integrity require adequate treatment. Lipid nanoparticles (LN) are recognized as promising drug delivery systems (DDS) in treating skin disorders. Solid lipid nanoparticles (SLN) together with nanostructured lipid carriers (NLC) exhibit excellent tolerability as these are produced from physiological and biodegradable lipids. Moreover, LN applied to the skin can improve stability, drug targeting, occlusion, penetration enhancement, and increased skin hydration compared with other drug nanocarriers. Furthermore, the features of LN can be enhanced by inclusion in suitable bases such as creams, ointments, gels (i.e., hydrogel, emulgel, bigel), lotions, etc. This review focuses on recent developments in lipid nanoparticle systems and their application to treating skin diseases. We point out and consider the reasons for their creation, pay attention to their advantages and disadvantages, list the main production techniques for obtaining them, and examine the place assigned to them in solving the problems caused by skin disorders.

show abstract

Lipid-Based Drug Delivery Systems in Regenerative Medicine

Cited by 19 publications

References 167 publications

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy

Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy

Lipid Nanoparticles and Liposomes for Bone Diseases Treatment

Lipid Nanoparticulate Drug Delivery Systems: Recent Advances in the Treatment of Skin Disorders

Contact Info

Product

Resources

About